Replies to post #1814 on Elbit Imaging Ltd (EMITF)

[midastouch017]

Healthcare firm 'excited' over China's innovation

By LIU ZHIHUA | chinadaily.com.cn | Updated: 2021-08-06 09:42

http://global.chinadaily.com.cn/a/202108/06/WS610c93a7a310efa1bd667122.html

As a large market with increasing emphasis on the use and advancement of technologies, particularly in medicine, China presents an opportunity for growth and innovation of technology. [Photo/IC]

China's staunch commitment to promoting high-quality development and further opening up its market to foreign investors and companies will help accelerate innovation, which will allow high-tech companies to flourish and help foreign enterprises to operate successfully in the nation, said a top executive of Insightec, a global healthcare company headquartered both in Haifa in Israel, and Miami in the United States.

Founded in Israel, Insightec is the first in the world to launch a magnetic resonance-guided focused ultrasound (MRgFUS) platform to treat targets in the brain for movement disorders without incisions.

Maurice R. Ferre, CEO and chairman of Insightec, said China's pursuit of high-quality development and deepening of reforms is beneficial for people and businesses alike.

As a large market with increasing emphasis on the use and advancement of technologies, particularly in medicine, China presents an opportunity for growth and innovation of technology, as well as for innovation-focused companies addressing the challenges of an aging population.

"As a foreign enterprise, we are excited to seize the available opportunities to expand our operations and services in China and cooperate with local providers and partners," he said, adding the company will continue to make investments in China.

The company is very bullish in China, and expects the country to be its largest market, thanks to the nation's huge domestic market with aging population, and cost-effectiveness of the company's products, Ferre said.

As China enters a new phase of dual-circulation development pattern and promotes higher-level opening-up, its adherence to improving the business environment and its innovation-driven strategy are providing stronger impetus to increase foreign investment, experts said.

Data from the Ministry of Commerce showed China's actual use of foreign capital surged to 607.84 billion yuan ($94 billion) in the first half, up 28.7 percent year-on-year and up 27.1 percent over the first-half figure of 2019.

In the healthcare sector, where a series of major policy reforms have been introduced since 2015, internationalization and innovation have become an inevitable trend in the country's pharmaceutical industry in order to encourage innovation and improve quality healthcare accessibility and affordability.

Zhang Fei, associate director of the Institute of Foreign Investment, which is part of the Chinese Academy of International Trade and Economic Cooperation, said China has provided substantial investment returns to many foreign-funded companies, making a solid contribution to the world economic recovery and the establishment of a globally open economy.

She predicted sectors related to technological revolution and industrial transformation, like high-end manufacturing, smart terminals, autonomous driving, sensors, 5G and digitalization, will become the key areas of foreign investment during the 14th Five-Year Plan period (2021-25).

Ferre said business environment in China for foreign companies has been very favorable, and while applying "a lot of regulatory rigor",Chinese authorities have been "receptive" and have given a pathway for approvals for the company's technology that provides incisionless treatment to patients suffering from essential tremor and tremor-dominant Parkinson's disease.

The company entered China in 2014 with an office in Shanghai, and thanks to the favorable business environment in China for foreign companies, its latest product, called the Exablate Neuro system, was smoothly introduced in the Chinese market.

[midastouch017]

?nsightec Announces Seoul National University Hospital Is Installing Exablate Neuro Platform
By INSIGHTEC Aug 8, 2021

https://www.kpvi.com/news/national_news/insightec-announces-seoul-national-university-hospital-is-installing-exablate-neuro-platform/article_95ce1f07-eab1-5e24-97ba-16f18ab2f0fe.html

Expanding patient access to incision-free Focused Ultrasound treatment

HAIFA, Israel and MIAMI, Aug. 9, 2021 /PRNewswire/ -- Insightec®, a global healthcare company focused on creating the next generation of patient care, announced Seoul National University Hospital is installing the company's Exablate® Neuro platform. The Exablate Neuro (Exablate 4000) platform uses Focused Ultrasound to ablate targets deep in the brain for a therapeutic effect.

"This is the first installation of our first-to-market Focused Ultrasound technology in a public hospital in South Korea," commented Ori Atar, Director of Asia Growth Markets at Insightec. "It is exciting to know that more patients will now have access to an incisionless treatment option."

"Focused Ultrasound provides a precision tool for neurosurgical treatments," Prof. Kim Seung Ki, Head of Neurosurgery SNUH explains. "Clinical evidence has demonstrated a positive impact on patient quality of life with a favorable safety profile."

There are 81 leading medical centers globally that have established Focused Ultrasound programs with the Exablate Neuro. Insightec partners with Huons, a manufacturer of pharmaceutical products and distributor of medical solutions, to bring Focused Ultrasound to Korean healthcare systems.

"Bringing advanced technology that improve people's health to the largest public hospital is a major milestone," says Key-An Um, CEO of Huons. "Medical centers are realizing the value that a Focused Ultrasound program can bring to patient care."

Insightec Media Contact

G&S Business Communications for Insightec

Elizabeth Mannheimer

+1 917.595.3034

[e-mail]

Logo- https://mma.prnewswire.com/media/1497639/INSIGHTEC_Logo.jpg

[midastouch017]

Insightec Announces FDA Approval of Exablate Neuro for the Treatment of Parkinson's Disease

The device is indicated for unilateral pallidotomy for medication-refractory patients with moderate to severe motor complications

https://www.prnewswire.com/news-releases/insightec-announces-fda-approval-of-exablate-neuro-for-the-treatment-of-parkinsons-disease-301414996.html

MIAMI, Nov. 3, 2021 /PRNewswire/ -- Insightec®, a global healthcare company creating the next generation of patient care by realizing the therapeutic power of acoustic energy, announced today that the U.S. Food and Drug Administration (FDA) has approved the Exablate® Neuro for treating advanced Parkinson's Disease patients suffering from mobility, rigidity, or dyskinesia symptoms.

The Exablate Neuro uses focused ultrasound waves to precisely target and ablate the globus pallidus (GPi) during a pallidotomy. The treatment is incisionless, does not require brain implants, and has less risk of infection than invasive surgery.

"Movement disorder neurologists now can offer their Parkinson's patients a less invasive surgical option as part of their treatment plan," Paul S. Fishman, MD, PhD, professor of neurology, pharmacology and neurobiology at the University of Maryland School of Medicine.

"This approval is significant in that it adds Focused Ultrasound as an incisionless surgical option to treat motor symptoms of Parkinson's disease," added Howard M. Eisenberg, MD, R.K. Thompson Professor, Department of Neurosurgery at the University of Maryland and Principal Investigator.

Parkinson's disease (PD), a neurodegenerative disorder, affects an estimated one million patients in the United States. Tremor, rigidity, slow movement (bradykinesia), and postural instability are the cardinal features of PD. When medication induces side effects or is not well tolerated, surgical treatments, such as Focused Ultrasound, may be considered.

"This expanded approval of clinical indications to treat Parkinson's Disease signifies the growing understanding and acceptance of Focused Ultrasound as an effective treatment modality," commented Maurice R. Ferré MD, Insightec CEO and Chairman of the Board of Directors. "More importantly, it drives our continued efforts to help transform the lives of people living with debilitating neurological and other conditions."

The Exablate Neuro device received approval by the FDA for the treatment of medication-refractory Essential Tremor in 2016 and for Tremor-dominant Parkinson's Disease in 2018. There are currently 37 medical centers in the United States using the Insightec Exablate Neuro device to treat patients with medication-refractory Essential Tremor and Tremor-dominant Parkinson's Disease.